Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Synergistic kvasi-living antibiotics (MDR platform)
- Development stage
- Preclinical
- Lead developer
- TRIZ Biopharma Innovations
- Modality
- Small Molecules
01
Overview
Synergistic kvasi-living antibiotics (MDR platform) is a preclinical-stage therapeutic approach developed by TRIZ Biopharma Innovations LLC to combat multidrug-resistant (MDR) bacterial infections. The technology utilizes a "quasi-living" (or "kvasi-living") mechanism that combines FDA-approved "enhancer" drugs—which act as bacterial growth activators—with conventional antimicrobials. Rather than attempting to kill bacteria immediately, the enhancers synchronize the bacterial population into a rapid growth phase. This metabolic shift causes the bacteria to lose their resistance mechanisms, disrupts biofilms, and halts the production of toxins and virulence factors, thereby restoring the efficacy of the co-administered antibiotics. The platform is specifically targeted toward treating infections caused by *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and multidrug-resistant tuberculosis.
- Other names
- Kvasi-living antibiotic approachQuasi-living antibiotic approachSynergistic kvasi-living antibiotics
Beyond the preview
Go deeper on Synergistic kvasi-living antibiotics (MDR platform).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synergistic kvasi-living antibiotics (MDR platform).